Oruka Therapeutics: 15min chart shows RSI overbought and KDJ death cross.

Oruka Therapeutics's 15-minute chart has triggered both RSI Overbought and KDJ Death Cross indicators on October 6, 2025 at 14:00. This suggests that the stock price has risen too quickly and is now unsupported by fundamental factors, indicating a shift in momentum towards the downside and potentially further decreases in stock price.

Oruka Therapeutics (ORKA) has recently experienced a significant shift in market sentiment, as indicated by the activation of both the Relative Strength Index (RSI) Overbought and the KDJ Death Cross indicators on its 15-minute chart on October 6, 2025, at 14:00 MoonLake rebounds despite downgrades prompted by trial setback^[1]. These technical indicators suggest that the stock price has risen too quickly and is now unsupported by fundamental factors, signaling a potential shift in momentum towards the downside and further decreases in stock price.

The RSI Overbought indicator typically signals that an asset may be overvalued, and the KDJ Death Cross is a bearish signal indicating a potential reversal in the trend. These combined signals suggest that investors should be cautious about the stock's current valuation and potential future performance.

While Oruka Therapeutics has shown promise with its lead candidate, ORKA-002, which targets hidradenitis suppurativa (HS), the company faces increasing competition from other biotech firms. Notably, MoonLake Immunotherapeutics (NASDAQ:MLTX) has experienced a setback in its Phase 3 VELA program for sonelokimab, a similar HS treatment. However, the company has a significant cash runway extending into 2028, supporting continued development in HS and other indications .

The market's reaction to Oruka Therapeutics' indicators suggests a potential overreaction to recent positive developments. Investors should carefully evaluate the company's fundamentals and the competitive landscape to make informed decisions. As the indicators suggest, the stock may be overvalued, and a correction could be imminent.